US2014154235A1PendingUtilityA1
Wound debridement compositions containing seaprose and methods of wound treatment using same
Est. expiryMay 12, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61P 43/00A61K 9/0019A61K 9/06A61K 47/38C12Y 304/21063A61K 47/44A61K 9/0014A61K 38/482A61K 47/10A61K 47/06A61P 17/02
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.
Claims
exact text as granted — not AI-modified1 . A method of debriding a wound that includes necrotic tissue comprising applying to the wound a composition comprising Seaprose, wherein application of the composition debrides necrotic tissue in the wound.
2 . The method of claim 1 , wherein the necrotic tissue is an eschar.
3 . The method of claim 1 , wherein the composition is topically applied to the wound.
4 . The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable topical carrier.
5 . The method of claim 1 , wherein the wound is a chronic wound.
6 . The method of claim 5 , wherein the chronic wound is a diabetic foot ulcer, a venous leg ulcer, an arterial leg ulcer, a decubitus ulcer, a stasis ulcer, a dermal ulcer, a burn, or a pressure ulcer.
7 . The method of claim 1 , wherein the composition includes 0.1 to 2% by weight of Seaprose.
8 . The method of claim 7 , wherein the composition includes 0.5 to 1% by weight of Seaprose.
9 . The method of claim 1 , wherein the Seaprose is isolated or purified Seaprose.
10 . The method of claim 1 , wherein the composition is formulated as a gel, cream, or ointment.
11 . The method of claim 1 , wherein the composition further comprises glycerin polyacrylate clatharate, glycerin, hydroxyethylcellulose, an emulsifying wax, or petrolatum, or any combination thereof.
12 . The method of claim 1 , wherein the composition is injected into the wound.
13 . The method of claim 12 , wherein the composition further comprises a pharmaceutically acceptable injectible carrier.
14 - 24 . (canceled)
25 . A topical composition for the debridement of wounds comprising a wound debridement effective amount of Seaprose and a pharmaceutically acceptable topical carrier.
26 . The topical composition of claim 25 , wherein the composition includes 0.1 to 2% by weight of Seaprose.
27 . The topical composition of claim 26 , wherein the composition includes 0.5 to 1% by weight of Seaprose.
28 . The topical composition of claim 25 , wherein the Seaprose is isolated or purified Seaprose.
29 . The topical composition of claim 25 , wherein the composition is formulated as a gel, cream, or ointment.
30 . The topical composition of claim 25 , wherein the composition is an ointment comprising petrolatum.
31 . The topical composition of claim 25 , wherein the composition is a gel comprising glycerin polyacrylate clatharate.
32 . The topical composition of claim 25 , wherein the composition is a gel comprising hydroxyethylcellulose.
33 . The topical composition of claim 25 , wherein the composition is a cream comprising glycerin and an emulsifying wax.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.